CyberKnife Prostate Cancer Planning Study Published in Leading Radiation Oncolo... (t doses of radiation (i.e. regions of th...)

CyberKnife Prostate Cancer Planning Study Published in Leading Radiation Oncology Journal

Date:4/8/2008

t doses of radiation (i.e., regions of the prostate expected to have large numbers of tumor cells receive higher doses of radiation than other parts of the prostate that may have a smaller amount of tumor cells).

About the CyberKnife(R) Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 40,000 patients worldwide and currently more than 125 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit http://www.accuray.com.

Safe Harbor Statement

The foregoing may contain certain forward-looking statements that involve risks and un
'/>"/>

SOURCE Accuray Incorporated
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related biology technology :

1. CyberKnife Users Meeting Highlights Major Clinical Data Milestones and Emerging Trends
2. CyberKnife Radiosurgery Used to Treat Lung Tumors at 90 Percent of Centers Worldwide
3. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
4. Varian Medical Systems Introduces New and Improved VariSeed(TM) 8.0 Software for Permanent Seed Prostate Brachytherapy Treatments
5. Tapestry Reports Third Quarter 2007 Financial Results and Preliminary Data From Its Phase 2 Prostate Cancer Trial
6. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
7. Center for Molecular Medicine Among First to Offer New FDA-Approved Test to Aid in Treatment of Prostate Cancer
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup
10. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound

Post Your Comments:

(Date:11/24/2009)... Health care employment grew by ...only one to show consistent growth during the U.S....ls remain in trouble, and health systems are comin...el, instead of just administrators. , ...are employment continued growing in October despit...

(Date:11/24/2009)...HANGHAI,Nov.24/PRNewswire-Asia/--ShanghaiBiolaxyan...(SFDA)hasapprovedthe,investigationalnewdrugapplica...ativeinsulinformulationtotreatdiabetes.ThisIND,app...study. , Diabetesisadisordercharacteristicofh...ofdiabetesoftenresultinseveremicro-and,macro-vascu...

(Date:11/24/2009)...SXVENTURE:HTL , TORONTO,Nov.24/PRNewswire-Fir...ttoCapitalInc.,aleadingproviderofadvancedlasersyst...yclinicmarkets,todayreportedoperationalandfinancia..., ,Q32009Highlights,-Revenuewas$1.46millioncompar....3percentcomparedwith66.1percentinQ3,2008,-Netloss...

(Date:11/24/2009)...OZEN,Italy,November24/PRNewswire/--HealthRoboticst...urewithagroupofselected,investors.Thisrecentlyform...thRoboticsCanada,Inc.andwillmarket,install,andsupp...hincludesthe,revolutionaryproductofferingsi.v.STAT...adaInc.willalsoprovideassistanceonan"asneeded,basi...

Breaking Biology Technology:The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 2 The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 3 The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 4 Biolaxy Secures IND Approval for Oral Insulin 2 Hamilton Thorne announces third quarter results 2 Hamilton Thorne announces third quarter results 3 Hamilton Thorne announces third quarter results 4 Hamilton Thorne announces third quarter results 5 Hamilton Thorne announces third quarter results 6 Hamilton Thorne announces third quarter results 7 Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 2

[0] The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close [0] Biolaxy Secures IND Approval for Oral Insulin [0] Hamilton Thorne announces third quarter results [0] Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada

...sia-FirstCall/ -- Genesis,Pharmaceuticals Enterpri... the,"Company"), a U.S. pharmaceutical company wit...c of China, today announced its financial results ...ed December 31, 2008. , , Second Quarter of Fis...million, up 24.1% from the corresponding quarter, ...

...tech Industry , , FT. LAUDERDALE, Fla., Feb. 17 ...full-service securities broker-dealer and investme... Newbridge BioVentures Division ("NBV"). NBV is de...or the biotech industry and related investment opp...ividual investors. , , We are pleased to announce...

...ences, Inc. (Nasdaq: HGSI ) today announced that...ase 3 clinical trial program to evaluate the effic...glutide) in the long-term treatment of type 2 diab... million milestone payment in the first quarter of.../prnh/20080416/HGSLOGO ) , , "We are delighted t...

Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 Newbridge Securities Corporation Forms BioVentures Division Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes

(Date:11/24/2009)...abby arteries from collapsing have been true life-...longer needed -- once the arteries are strengthene...d no choice but to leave them in place. , Prof. ...nt of Biomedical Engineering has developed a new p...ere they,re needed, then dissolves. , "Our new c...

(Date:11/24/2009)...er 24, 2009) -- The Wildlife Conservation Society ...last remaining population of Siberian tigers has l...e of poaching and habitat loss. , WC...ls of what needs to be done to protect remaining p... The report was released by the Siberian Tige...

(Date:11/24/2009)...9) New research on bacterial communities througho...ctable temporal patterns, suggesting that scientis...toring climate change in the polar regions. The st...e National Academy of Sciences Early Edition, sho...ifted synchronously over time, correlating with se...

Breaking Biology News(10 mins):A coating for life 2 Report shows dramatic decline in Siberian tigers 2 Researchers establish common seasonal pattern among bacterial communities in Arctic rivers 2 Virginia Mason Signs with Carefx to Implement Fusionfx Solution Suite 50490 1 Virginia Mason Signs with Carefx to Implement Fusionfx Solution Suite 50490 2 Virginia Mason Signs with Carefx to Implement Fusionfx Solution Suite 50490 3 Exiqon Announces 2009 North American Grant Award Winners 50486 1 Exiqon Announces 2009 North American Grant Award Winners 50486 2 Exiqon Announces 2009 North American Grant Award Winners 50486 3 The Meetings Industry Stirred But Not Shaken by Current Economic Setbacks Patriot Meetings Announces Their 360 Degree Program that Ensures Success 50482 1 The Meetings Industry Stirred But Not Shaken by Current Economic Setbacks Patriot Meetings Announces Their 360 Degree Program that Ensures Success 50482 2 The Meetings Industry Stirred But Not Shaken by Current Economic Setbacks Patriot Meetings Announces Their 360 Degree Program that Ensures Success 50482 3

[0] A coating for life [0] Report shows dramatic decline in Siberian tigers [0] Researchers establish common seasonal pattern among bacterial communities in Arctic rivers

...r forum for health care executives to explore a my...aders. The 2008 Congress will include senior execu...argest employers, hospitals, health systems, healt... government. , One of the programs many highlight...re key health care advisors to Presidential hopefu...

...iversity have confirmed for the first time that a ...least the past 23 years and will likely remain the...fe in the area. , Steve DiMarco, associate profes...tudied dead zones in the Gulf of Mexico for more t...Texas coast extends from the Texas-Louisiana borde...

...omen use hormone replacement therapy (HRT) as a me... In a recent University of Missouri study, researc... synthetic progestin, could be a major factor in p...archers have compelling evidence that using an ant...tumors, or a small molecular drug, known as PRIMA,...

Other Biology News:5th Annual World Health Care Congress April 21-23, Washington, D.C. 2 Researchers confirm dead zone off Texas coast since 1985 2 MU researcher links hormone replacement therapy to breast cancer 2

5th Annual World Health Care Congress April 21-23, Washington, D.C.Researchers confirm dead zone off Texas coast since 1985 MU researcher links hormone replacement therapy to breast cancer

Sheep Anti-FLECAINIDE Polyclonal Antibody, Unconjugated from AbD Serotec

...or use in refrigerators, freezers, or liquid nitro...ks. Four vibrant colors allow for color coding to ... liquid nitrogen drainage or promote cool air circ...hich holds 81 tubes. Box dimensions: 13 x 13 x 5...

Rhesus Monkey IFN-Alpha from Cell Sciences

Rabbit Anti-HAX1 Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.

Biology Products:

Sheep Anti-FLECAINIDE Polyclonal Antibody, Unconjugated from AbD Serotec White 2" Freezer Storage Boxes With 9 x 9 Grid from PGC Scientifics Rhesus Monkey IFN-Alpha from Cell Sciences Rabbit Anti-HAX1 Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.

CyberKnife Prostate Cancer Planning Study Published in Leading Radiation Oncolo...(t doses of radiation (i.e. regions of th...)